Skin cancer breakthrough delivers second act for Moderna's mRNA vaccines
A personalised vaccine developed by Moderna and Merck reduced the recurrence of melanoma in a large, late-stage trial, raising expectations for treating the deadliest form of skin cancer and showing the promise of the embattled mRNA technology. The trial met its main goal as the vaccine, combined with Merck’s immune drug Keytruda, prevented the cancer’s return after it was surgically removed more…
We haven't written up this one. The National Business has the full story — the link below goes straight to it.
This story
This is one outlet's version. Read the fullest account.
- Skin cancer breakthrough delivers second act for Moderna's mRNA vaccines thenationalnews.com
